FindTrial
Sign In

Medical records based study on the efficacy and safety of long-term use of tenofovir propofol fumarate in patients with chronic viral hepatitis B

Study on the efficacy and safety of long-term use of tenofovir propofol fumarate in patients with chronic viral hepatitis B

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100050189
Enrollment
Unknown
Registered
2021-08-21
Start date
2021-08-21
Completion date
Unknown
Last updated
2022-04-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic viral hepatitis B

Interventions

case group:Nil

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Newly diagnosed or previously diagnosed patients with chronic viral hepatitis B who visited the Outpatient Department of Infection, West China Hospital of Sichuan University from January 2019 to December 2020 were included; 2. Antiviral indications; 3. TAF is an antiviral drug that has been taken up to now.

Exclusion criteria

Exclusion criteria: 1. Patients with previous kidney disease, combined with hepatitis A, C, D, and E virus infection, alcoholic liver disease, non-alcoholic liver disease, drug liver disease, autoimmune liver disease, hereditary liver disease and other diseases that may cause chronic liver dysfunction.

Countries

China

Contacts

Public ContactChen Enqiang

West China Hospital, Sichuan University

chenenqiang1983@hotmail.com+86 18980606517

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026